null

null

null

null

null

null

null

null

null

Minimal debt; Sensus carries near-zero long-term debt with cash-positive balance sheet, so a 20% rate rise has negligible interest expense impact.

Low sensitivity; minimal borrowings mean rising rates primarily affect equipment financing costs for customers, potentially slowing capital equipment purchases.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Key chokepoints: (1) Taiwan/China semiconductor fabrication for X-ray tube components; (2) China-sourced electronic subassemblies amid export control risk.

Limited international revenue (~15-20% of total); exposure concentrated in Europe (EUR) and modest APAC presence; EUR devaluation poses modest single-digit revenue headwind.

Predominantly US-based (~80%+ revenue); secondary markets are EU and select APAC countries; EUR/USD and AUD/USD are primary FX exposure vectors.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Moderate risk; reliance on a limited number of X-ray tube and power supply manufacturers; no single vendor publicly confirmed >30% but concentration is meaningful.

Medical device hardware manufacturer; cloud dependency is minimal—devices operate standalone, so cloud termination would not halt core product delivery.

Service contract and software component revenues have some cloud/connectivity elements, but disruption impact is limited and migration feasible within 30 days.

Low API coupling risk; proprietary device ecosystem with limited third-party API dependencies; service software is internally developed with minimal external API reliance.

Not applicable; revenue derives from medical device sales and service contracts—no investment contract or token structure triggers Howey Test concerns.

Very High

Moderate GDPR/CCPA exposure; devices capture patient treatment data; compliance obligations exist but scope is limited relative to pure software/health data companies.

Low antitrust risk; Sensus holds a niche position in superficial radiation therapy; market is small and includes larger competitors (Xstrahl), limiting dominance concerns.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional (~70-75% capital equipment sales); recurring revenues (~25-30%) from service contracts and SaaS-like treatment tracking software (Sculptura).

Primary: capital equipment unit sales; secondary: annual service/maintenance contracts and per-use or subscription software (Sculptura platform) tied to installed base.

Premium pricing supported by FDA clearance and clinical efficacy; vulnerable to reimbursement rate cuts (CPT code changes) which could compress dermatology practice ROI on equipment.

Moderate-to-high; limited direct competitors in office-based SRT, strong clinical differentiation, but Medicare/insurance reimbursement caps ultimate customer willingness to pay.

43.2% Gross Margin (Strong (40-60%))

Low free-rider risk; proprietary consumables and service contracts create captive recurring revenue; no open-source or free alternative to SRT devices exists.

Sublinear; doubling revenue requires modest incremental headcount in sales and field service; R&D and manufacturing scale without proportional headcount growth.

Moderate marginal cost of growth; hardware COGS scales with units, but software and service margins improve at scale; gross margin ~50-55% provides operating leverage.

Not applicable; Sensus does not operate a franchise network.

At 10x scale, CAC likely decreases as brand recognition grows; LTV/CAC remains favorable given service contract attach rates, but sales cycle length constrains rapid scaling.

Weak network effects; installed base drives software stickiness and clinical data aggregation, but device utility does not meaningfully increase as more users adopt.

-18.1% Return on Assets (Negative equity)

Moderate resilience; non-melanoma skin cancer treatment is medically necessary, but elective dermatology capital spending by practices declines in recessions, pressuring equipment sales.

Dermatology private practices and dermatologists (~60-70% of revenue); concentration risk is notable as top accounts represent meaningful share of annual equipment placements.

Radiation oncology centers and multi-specialty clinics (~20-30%); less concentrated, longer sales cycles, but higher deal values and stronger service contract attachment.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.7% CapEx / Revenue (Low-CapEx Asset-Light)

0001494891

SRTS